MedicaSafe Inc — Department of Health and Human Services SBIR Phase I: NIDA

Description

DESCRIPTION provided by applicant This SBIR Phase I application proposes development of MedicaSafeandapos s Implicit Prescription Abuse Cognitive Toolkit IMPACT a technology enabled suite of cognitive assessment tools to significantly add to physiciansandapos ability to detect signs of opioid misuse and abuse in patients on opioid therapies MedicaSafeandapos s IMPACT will comprise prescription opioid specific versions of two of the most validated implicit measures the Implici Association Test IAT and Drug Stroop Task IMPACT assessments will be brief computerized measures that will inform physicians of the specific unconscious opioid related cognitions of their patients that affect substance use behaviors significantly improving upon the measures currently available to providers and improving clinical care overall for patients on opioid therapy The use of prescription opioids to treat chronic non cancer pain has increased at a staggering pace over the last two decades Concern over the misuse and abuse of prescription opioids has led to new actions by the U S Food and Drug Administration FDA to implement safe use measures such as Risk Evaluation and Mitigation Strategies REMS Although concern over the epidemic of prescription opioid abuse continues to increase more than million Americans suffer from chronic pain each year causing significant impairment in physical and emotional health To address this dual public health challenge key decision makers in the field now recommend a balanced approach that stresses judicious opioid prescribing and ongoing risk monitoring New advancements in assessment strategies are needed to enable a balanced approach that will best address patient suffering while mitigating the misuse and abuse of prescription opioids Recent findings in neuroscience have allowed researchers to gain insight into the unconscious thoughts and motivations of substance users This Phase I proposes to extend these advancements to the study of prescription opioid use in order to address the public health challenge of prescription opioid misuse and abuse Phase I will involve the empirical development and validation of the proposed implicit measures of prescription opioid misuse An expert panel of key opinion leaders in implicit measure methodology implicit cognition and addiction will assist MedicaSafe staff in this goal Upon development of the implicit assessments a validation study evaluating the ability of MedicaSafeandapos s implicit assessments to add to the current most validated explicit screeners and ongoing monitors of opioid misuse will be conducted at a pain management clinic The focus of this Phase I will be to establish the implicit assessmentsandapos validity as well as their clinical utility in detecting opioid misuse above ad beyond the current assessment strategies available to physicians PUBLIC HEALTH RELEVANCE Chronic pain is a serious public health problem However the use of prescription opioids for pain management has been associated with an epidemic of abuse that healthcare providers are ill equipped to address This research will develop two innovative measures of opioid misuse to be used at the beginning of opioid therapy and throughout the course of treatment that will significantly improve the tools available to healthcare providers to address the dual public health challenges of prescription opioid abuse and chronic pain